|
Report Date : |
05.09.2013 |
IDENTIFICATION DETAILS
|
Name : |
BC WORLD PHARM.
CO., LTD. |
|
|
|
|
Registered Office : |
11, Samgun-ri, Ganam-myeon, Yeoju-gun,
Gyeonggi-do, Korea |
|
|
|
|
Country : |
South Korea |
|
|
|
|
Financials (as on) : |
31.12.2012 |
|
|
|
|
Date of Incorporation : |
19.03.1980 |
|
|
|
|
Com. Reg. No.: |
139-81-11269 |
|
|
|
|
Legal Form : |
Co., Ltd by shares |
|
|
|
|
Line of Business : |
Manufacture of
Finished Medicaments. |
|
|
|
|
No. of Employees : |
203 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
South Korea |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SOUTH KOREA - ECONOMIC OVERVIEW
South Korea over the past four decades has demonstrated incredible growth and global integration to become a high-tech industrialized economy. In the 1960s, GDP per capita was comparable with levels in the poorer countries of Africa and Asia. In 2004, South Korea joined the trillion dollar club of world economies, and is currently the world's 12th largest economy. Initially, a system of close government and business ties, including directed credit and import restrictions, made this success possible. The government promoted the import of raw materials and technology at the expense of consumer goods, and encouraged savings and investment over consumption. The Asian financial crisis of 1997-98 exposed longstanding weaknesses in South Korea's development model including high debt/equity ratios and massive short-term foreign borrowing. GDP plunged by 6.9% in 1998, and then recovered by 9% in 1999-2000. Korea adopted numerous economic reforms following the crisis, including greater openness to foreign investment and imports. Growth moderated to about 4% annually between 2003 and 2007. Korea''s export focused economy was hit hard by the 2008 global economic downturn, but quickly rebounded in subsequent years, reaching 6.3% growth in 2010. The US-South Korea Free Trade Agreement was ratified by both governments in 2011 and went into effect in March 2012. Throughout 2012 the economy experienced sluggish growth because of market slowdowns in the United States, China, and the Eurozone. The incoming administration in 2013, following the December 2012 presidential election, is likely to face the challenges of balancing heavy reliance on exports with developing domestic-oriented sectors, such as services. The South Korean economy''s long term challenges include a rapidly aging population, inflexible labor market, and heavy reliance on exports - which comprise half of GDP.
Source
: CIA
|
Company
Name |
BC WORLD PHARM.
CO., LTD. |
|
Registered Address |
11, Samgun-ri, Ganam-myeon, Yeoju-gun,
Gyeonggi-do, Korea (New Address System : 872-23, Yeojunam-ro,
Ganam-myeon, Yeoju-gun, Gyeonggi-do, Korea) |
|
Zip Code |
469-884 |
|
Tel |
+82-31-881-6800 |
|
Fax |
+82-31-881-0115 |
|
E-mail |
master@bcwp.co.kr;eslee322@bcwp.co.kr |
|
Website |
www.bcwp.co.kr |
|
Trading Address |
3rd.Fl., Kyeong Bldg, 1184-8, Gaepo
4-dong, Gangnam-gu, Seoul, Korea (New Address System : 78, Gaepo-ro 22-gil,
Gangnam-gu, Seoul, Korea) |
|
Tel |
+82-2-2182-0400 |
|
Fax |
+82-2-574-5073 +82-2-574-5064 |
|
Type |
Export/Import |
|
Industry |
Manufacture of Finished Medicaments |
|
Main Business |
Narcotic, Antiepileptic, Antihplogistics, Skeletel Musche Relexants,
Autonomic Nervous, Circulartory System, Digestive Organ System, Antibiotics |
|
Sub
Business |
|
|
Established (mm/dd/yyyy) |
03/19/1980 |
The Subject owns
the premises of registered HQ address.
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Nonsteroidal anti inflammatory drugs NSAIDs(51142100) |
|
Sell |
Morphine sulfate(51142206) |
|
Sell |
Dental drugs(51212100) |
|
Sell |
Antimetabolites(51111600) |
|
Sell |
Drugs used for congestive heart failure(51121900) |
|
Sell |
Antiulcer and related gastrointestinal GI drugs(51171900) |
|
Sell |
Drugs used for gallbladder disease(51172000) |
|
Sell |
Antifungal drugs(51101800) |
|
Name |
Hong Sung-Han (Steve H.) |
|
Address |
Suite 108-1503, 2311-12, Nambusunhwan-ro,
Seocho-gu, Seoul, Korea |
|
Date of Birth |
10/26/1957 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
|
Capital (KRW) |
993,625,000 |
||||||||||||||||||||||||||||||
|
Employees |
203 |
||||||||||||||||||||||||||||||
|
Formation |
Co., Ltd by shares Venture Business |
||||||||||||||||||||||||||||||
|
Bank Details |
Industrial Bank of Korea Woori Bank Hana Bank |
||||||||||||||||||||||||||||||
|
Corporate Registered No. |
124311-0005515 |
||||||||||||||||||||||||||||||
|
Business Registered No. |
139-81-11269 |
||||||||||||||||||||||||||||||
|
Permit & Licenses |
Int’l Trade No.: 14003789 |
||||||||||||||||||||||||||||||
|
Shareholder Position |
|
||||||||||||||||||||||||||||||
|
Company History |
03/19/1980 Incorporated as Hyeryung Pharm
Co., Ltd. 11/1984 Changed company name to Kukdong
Pharm Co., Ltd. 07/27/2000 Designated as a Venture Business 01/02/2007 Moved to the present HQ address
from 430-1, Nonhyeon-dong, Namdong-gu, Incheon, Korea 01/11/2007 Changed company name to the
present name 02/2007 Designated as an INNO-BIZ Company 07/10/2009 Decreased capital to 800,000
shares from 1,000,000 shares 07/30/2009 Increased capital to
1,133,325,000 KRW from 1,000,000,000 KRW 08/02/2011 Increased capital to 993,625,000
KRW from 963,325,000 KRW 08/03/2011 Designated as a Venture Business
again |
||||||||||||||||||||||||||||||
|
|
|
Management
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Date |
|
President & CEO |
Mr. |
Hong Sung-Han (Steve H.) |
Male |
Korean |
02/18/2009 |
|
Director |
Mr. |
Yoo Nam-Sik |
Male |
Korean |
02/18/2009 |
|
Director |
Mr. |
Lee Seung-Cheol |
Male |
Korean |
02/18/2009 |
|
Auditor |
Mr. |
Sung Young-Cheol |
Male |
Korean |
03/31/2012 |
|
Auditor |
Mr. |
Jung Sang-Soo |
Male |
Korean |
03/31/2012 |
|
Director |
Mr. |
Cho Jae-Hyun |
Male |
Korean |
11/05/2009 |
|
Director |
Mr. |
Park Jung-Kyu |
Male |
Korean |
10/05/2009 |
|
Supervisor |
Mr. |
Kim Kyung-Kook |
Male |
Korean |
10/05/2009 |
|
Supervisor |
Mr. |
Lim Han-Soo |
Male |
Korean |
02/08/2010 |
Financials
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
25,496,244,349 |
31,322,965,130 |
2,046,613,067 |
|
|
2011 |
26,749,225,154 |
31,513,905,321 |
2,600,119,264 |
|
2010 |
25,064,046,804 |
28,485,696,530 |
3,084,851,652 |
|
2009 |
26,682,341,616 |
23,443,926,495 |
3,029,470,516 |
|
2008 |
23,909,624,213 |
17,095,652,927 |
1,546,172,370 |
|
2007 |
14,023,572,824 |
13,399,307,005 |
2,630,960,349 |
|
2006 |
10,845,319,466 |
12,938,797,406 |
-6,246,842,782 |
|
2005 |
11,924,039,995 |
18,742,669,144 |
303,574,166 |
|
2004 |
10,590,519,959 |
17,637,674,431 |
489,992,462 |
|
Authorized Capital(KRW) |
4,000,000,000 |
|
Paid-Up Capital(KRW) |
993,625,000 |
|
Total Issued Shares |
198,725 (Common : 166,000 / Preferable : 32,725) |
|
Unit : Korean Won |
As of 12/31/2012 |
As of 12/31/2011 |
As of 12/31/2010 |
|
Total Assets |
31,322,965,130 |
31,513,905,321 |
28,485,696,530 |
|
Current Assets |
22,847,391,127 |
23,672,232,788 |
20,637,239,074 |
|
-Quick Assets |
15,750,228,639 |
17,290,618,400 |
15,689,090,453 |
|
-Inventories |
7,097,162,488 |
6,381,614,388 |
4,948,148,621 |
|
Fixed Assets |
8,475,574,003 |
7,841,672,533 |
7,848,457,456 |
|
-Investment |
326,190,209 |
256,440,270 |
186,571,414 |
|
-Tangibles |
5,315,844,617 |
5,468,159,669 |
5,641,194,761 |
|
-Intangibles |
625,374,175 |
629,174,494 |
678,300,101 |
|
-Others |
2,208,165,002 |
1,487,898,100 |
1,342,391,180 |
|
Total Liabilities |
8,692,303,796 |
10,827,222,054 |
12,203,033,527 |
|
Current Liabilities |
4,329,142,827 |
8,660,183,781 |
9,336,922,320 |
|
Fixed Liabilities |
4,363,160,969 |
2,167,038,273 |
2,866,111,207 |
|
Capital Stock |
993,625,000 |
993,625,000 |
963,325,000 |
|
Capital Surplus |
5,715,020,400 |
5,715,020,400 |
3,935,420,400 |
|
Profit Surplus |
15,922,015,934 |
14,318,037,867 |
11,813,917,603 |
|
Capital Adjustment |
- |
-340,000,000 |
-430,000,000 |
|
Total Equity |
22,630,661,334 |
20,686,683,267 |
16,282,663,003 |
|
Liab. & Shareholder’s Equity |
31,322,965,130 |
31,513,905,321 |
28,485,696,530 |
|
Current Liabilities |
4,329,142,827 |
8,660,183,781 |
9,336,922,320 |
|
Trade Payables |
28,490,433 |
53,792,179 |
80,625,359 |
|
Short-Term Borrowings |
1,700,000,000 |
5,800,000,000 |
6,760,000,000 |
|
Current Portion of Long-Term Debts |
1,101,905,000 |
1,175,020,000 |
1,099,980,000 |
|
Account Payables |
267,689,581 |
91,684,173 |
167,124,719 |
|
Advance Receipts |
35,832,664 |
13,815,306 |
12,900,000 |
|
Withholdings |
89,635,646 |
91,514,825 |
76,630,072 |
|
VAT Withhold |
319,632,307 |
349,659,278 |
139,667,106 |
|
Accrued Expenses |
785,957,196 |
836,014,850 |
751,311,894 |
|
Provisions for Refund |
- |
248,683,170 |
248,683,170 |
|
Fixed Liabilities |
4,363,160,969 |
2,167,038,273 |
2,866,111,207 |
|
Long-Term Borrowings |
4,107,715,000 |
1,909,620,000 |
2,585,640,000 |
|
Provision for Severance & Retirement |
259,330,950 |
261,169,780 |
284,048,090 |
|
Unit : Korean Won |
As of 12/31/2012 |
As of 12/31/2011 |
As of 12/31/2010 |
|
Sales |
25,496,244,349 |
26,749,225,154 |
25,064,046,804 |
|
Cost of Sold Goods |
12,230,007,830 |
12,190,920,514 |
10,945,421,128 |
|
Gross Profit |
13,266,236,519 |
14,558,304,640 |
14,118,625,676 |
|
Selling & Admin. Expenses |
11,260,198,889 |
11,190,092,658 |
10,717,191,544 |
|
Operating Income |
2,006,037,630 |
3,368,211,982 |
3,401,434,132 |
|
Non-Operating Income |
539,316,352 |
357,302,659 |
282,606,344 |
|
Non-Operating Expenses |
492,055,369 |
1,120,999,573 |
550,733,334 |
|
Income Before Taxes |
2,053,298,613 |
2,604,515,068 |
3,133,307,142 |
|
Income Taxes Expenses |
6,685,546 |
4,395,804 |
48,455,490 |
|
Net Income |
2,046,613,067 |
2,600,119,264 |
3,084,851,652 |
|
Unit : Korean Won |
As of 12/31/2012 |
As of 12/31/2011 |
As of 12/31/2010 |
|
Cash Flows from Operating |
4,549,392,440 |
1,461,994,936 |
50,649,547 |
|
-Net Income |
2,046,613,067 |
2,600,119,264 |
3,084,851,652 |
|
-Exp. without Cash Outflow |
2,292,988,322 |
2,474,496,634 |
2,014,346,730 |
|
-Revenue without Cash Inflows |
-249,491,260 |
-29,028,525 |
-499,000 |
|
-Changes in Asset/ & Liability |
459,282,311 |
-3,583,592,437 |
-5,048,049,835 |
|
Cash Flows from Investing |
-2,751,928,659 |
-1,916,167,127 |
-4,841,200,686 |
|
-Cash Inflow from Investing |
474,009,090 |
592,839,552 |
1,101,622,462 |
|
-Cash Outflows for Investing |
-3,225,937,749 |
-2,509,006,679 |
-5,942,823,148 |
|
Cash Flows from Financing |
-1,442,946,597 |
678,576,242 |
4,744,985,312 |
|
-Cash Inflows from Financing |
3,934,708,403 |
2,834,555,242 |
5,209,584,812 |
|
-Cash Outflows from Financing |
-5,377,655,000 |
-2,155,979,000 |
-464,599,500 |
|
Increase/Decrease in Cash |
354,517,184 |
224,404,051 |
-45,565,827 |
|
Cash at the Beginning of Year |
1,074,029,247 |
849,625,196 |
895,191,023 |
|
Cash at the End of Year |
1,428,546,431 |
1,074,029,247 |
849,625,196 |
|
Main Products & Services |
Narcotic, Antiepileptic, Antihplogistics, Skeletel Musche Relexants, Autonomic
Nervous, Circulartory System, Digestive Organ System, Antibiotics |
|
Detailed Products Spec. |
|
|
Technologies Acquired |
|
|
Competitors |
CHOONGWAE PHARMA CORP. CHOONGWAE BLDG., 698, SINDAEBANG 1-DONG, DONGJAK-GU,
SEOUL, KOREA TEL:+82-2-840-6777 FAX:+82-2-841-1213 GEO-YOUNG CORPORATION 421-1, YEONHUI-DONG, SEODAEMUN-GU, SEOUL,
KOREA TEL:+82-2-3662-8222 FAX:+82-2-3141-6492 JEIL PHARMACEUTICAL CO., LTD. 745-5, BANPO 1-DONG, SEOCHO-GU, SEOUL,
KOREA TEL:+82-2-549-7451 FAX:+82-2-549-7478 |
|
Cooperative Enterprise |
-Insured Company DONGBU INSURANCE CO., LTD.(110111-0095285) HANWHA GENERAL INSURANCE CO., LTD.(110111-0006456) |
Sales by Region
(Activity & Markets)
|
Sales/ Unit :Mil KRW |
2012 |
2011 |
2010 |
|
Export |
|
|
|
|
Domestic |
|
|
|
|
Total |
|
|
|
The Subject deals
with the companies in Italy, UK and Middle East.
Court Action
|
Case No. |
Court |
Plaintiff(s)/
Creditor(s)/ Applicant(s) |
Defendant(s)/
Debtor(s)/ Respondent(s) |
Cause |
Amount (Million KRW) |
Status |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No.
--
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs. 67.03 |
|
|
1 |
Rs. 104.32 |
|
Euro |
1 |
Rs. 88.24 |
INFORMATION DETAILS
|
Report
Prepared by : |
NIS |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.